By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NewLink Genetics 

2901 South Loop Drive
Suite 3900
Ames  Iowa  50010  U.S.A.
Phone: 515-296-5555 Fax: 515-296-5557


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
NewLink Genetics (NLNK) Redeemed Itself After Melanoma Data Wows In Mid-Stage Study 9/7/2017 6:22:50 AM
NewLink Genetics (NLNK) Reports Second Quarter 2017 Financial Results and Updates Indoximod Program 7/28/2017 8:05:03 AM
NewLink Genetics (NLNK) Announces First Patient Dosed In Phase I Study Of IDO Pathway Inhibitor NLG802 7/27/2017 8:23:16 AM
NewLink Genetics (NLNK) Receives Notice Of Allowance From USPTO Covering Indoximod Salts And Prodrugs 7/10/2017 8:29:46 AM
NewLink Genetics (NLNK) To Host Its Second Quarter 2017 Financial Results Conference Call On July 28, 2017 7/7/2017 8:22:25 AM
Positive Phase Ib Data For NewLink Genetics (NLNK)’ IDO Pathway Inhibitor, Indoximod, In Combination With Chemotherapy For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Presented At The European Hematology Association Congress In Madrid, Spain 6/23/2017 7:32:12 AM
NewLink Genetics (NLNK) Stock Plunges After Genentech (RHHBY) Bails on $1 Billion+ IDO Deal 6/8/2017 5:47:08 AM
NewLink Genetics (NLNK)’ Indoximod + PROVENGE Results In Statistically Significant Improvement In Radiographic Progression-Free Survival (rPFS) For Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) In Phase II Trial 6/5/2017 10:34:17 AM
NewLink Genetics (NLNK) Release: Results From Clinical Trial Of Indoximod Plus Chemotherapy For Patients With Metastatic Breast Cancer 6/5/2017 9:53:35 AM
Data From Clinical Study Of NewLink Genetics (NLNK)’ IDO Pathway Inhibitor, Indoximod, To Be Presented At The 22nd European Hematology Association Congress 5/18/2017 9:07:30 AM
12345678910...
//-->